黄仪有 博士 研究员 博士/硕士生导师
邮箱：hyyou@hainanu.edu.cn
1. 教育背景及工作经历
2021. 09 - 海南大学药学院，研究员
2020. 09 - 2021. 08 中山大学药学院，特聘副研究员
2018. 09 - 2020. 08 中山大学药学院，博士后
2015. 09 - 2018. 06 中山大学药学院，药物化学博士
2011. 09 - 2014. 06 中山大学药学院，药物化学硕士
2007. 09 - 2011. 06 南方医科大学药学院，药学学士
2. 科研情况
“靶标结构及新药发现”团队负责人，围绕磷酸二酯酶等重要药物靶点，开展结构生物学与药物化学交叉研究。依托X射线晶体学解析靶点原子级结构与分子调控机制，结合人工智能技术进行天然产物及苗头化合物的结构优化，研发临床前候选药物，助力重大疾病创新药物研发。先后主持国家自然科学基金面上项目/青年基金、海南省自然科学基金优青项目/面上项目等7项基金，并在国内外重要学术期刊如Proc Natl Acad Sci USA、J Med Chem、Acta Pharm Sin B、Org Lett等发表SCI论文40余篇，含（并列）一作/（共同）通讯论文30余篇，授权发明专利4项。
3. 研究领域
（天然）药物化学及结构药理学
4. 代表性项目
1） 国家自然科学基金面上项目，2023 - 2026，主持
2） 国家自然科学基金青年基金，2021 - 2023，主持
3） 海南省自然科学基金优青项目，2024 - 2027，主持
4） 海南省自然科学基金面上项目，2022 - 2023，主持
5）海南大学科研启动经费，2021 - 2026，主持
5. 代表性成果
1) Zhang, F.#; Zheng, T.#; Wang, X.#; Chen, Y.; Zhang, F.; Liu, X.; Wang, S.; Yang, G.; Xie, S.; Wu, Q.; Xu, C.; Zhou, Q.; Wu, D.*; Luo, H.-B.*; Huang, Y.-Y.* Structure-based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Anti-Psoriasis Effects. J. Med. Chem. 2025, 68, 6789−6803.
2) Zhang, F.#; Yuan, H.#; Yao, S.; Yang, D.; Wu, J.; Chen, J.; Wang, Q.*; Huang, Y.-Y.*; Luo, H.-B.; Guo, L.* Structure-Based Optimization of Imidazopyridine Derivatives as Selective and Orally Bioavailable Phosphodiesterase 10A Inhibitors with Reduced Blood-Brain Barrier Penetration for the Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2025,68, 25290-25306.
3) Huang, Y.-Y.#; Luo, X.#; Zhang, K. #; Liang, Y.; Zhang, F.; Liao, G.; Xie, S.; Huang, P.-L.; Hou, S.; Zhou, Q.*; Zou, Y.*; Luo, H.-B.* Structure-based Optimization of Isoaurostatin as Novel PDE4 Inhibitors with Anti-fibrotic Effects. Chin. Chem. Lett. 2025, 36, 110586.
4) Liu, X.#; Gu, W.#; Zhou, Y.#; Wu, L.; Chen, Z.; Xiao, K.; Cao, Y.; Wu, Q.; Cao, Z.; Huang, S.*; Li, B.*; Huang, Y.-Y.*; Luo, H.-B. Discovery of Pinoresinol Dimethyl Ether as a Natural PDE4 Inhibitor with Anti-psoriatic Effects. Bioorg. Chem. 2026, 169, 109414.
5) Sang, Z.-P.#; Xue, T.#; Xing, Q.-R.#; Zhang, Q.-Y.; Chen, H.-S.; Wang, X.; Zhang, F.-R.; Fu, W.-L.; Dong W.; Huang, S.*; Huang, Y.-Y.*; Luo, H.-B.* Discovery of α-mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Alzheimer's Disease: An Artificial Intelligence-driven Synergized Strategy. Chin. Chem. Lett. 2026, 37, 111318.
6) Yang, F.#; Guo, Q.#; Chen, M.#; Wang, W.; Chen, X.; Zhang, S.; Bian, H.; Li, J.; Jiao, Z.; Wang, Q.; Xiong, W.; Huang, Y.-Y.*; Liu, Y.*; Xu, C.*; Huang, L.* Discovery of Novel 2,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridine-7-one Derivatives as PDE2 Inhibitors with Alzheimer's Disease Therapeutic Potential. Eur. J. Med. Chem. 2026, 302, 118302.
7) Chen, Z.#; Shi, Y.#; Zhong, F.; Zhang, K.; Zhang, F.; Xie, S.; Cheng, Z.; Zhou, Q.*; Huang, Y.-Y.*; Luo, H.-B.* Discovery of Amentoflavone as a Natural PDE4 Inhibitor with Anti-fibrotic Effects. Chin. Chem. Lett. 2025, 36, 109956.
8) Yuan, H.#; Zhang, F.#; Huang, H.#; Wu, J.; Yang, Y.; Huang, W.; Yang, D.; Li, Z.; Li, Z.; Huang, L.; Huang, Y.-Y.*; Luo, H.-B.*; Guo, L.* Discovery of 3-trifluoromethyl-substituted Pyrazoles as Selective Phosphodiesterase 10A Inhibitors for Orally Attenuating Isoprenaline-induced Cardiac Hypertrophy. Chin. Chem. Lett. 2025, 36, 109965.
9) Zhao, Z.-J.#; Jiang, M.-Y.#; Huang, M.-X.#; Yang, Y.-Y.; Feng, L.-L.; Zhang, C.; Huang, Y.-Y.*; Luo, H.-B.*; Wu, Y.* Design, Synthesize and Evaluation of Dihydropyrimidine Derivatives as Selective PDE1 Inhibitors for the Treatment of Liver Fibrosis. J. Med. Chem. 2024, 67:8309-8322.
10) Zhang, Q.#; Sun, L.#; Wu, L.#; Wang, X.; Chen, L.; Chen, Y.; Liu, Y.; Gu, W.; Shi, D.; Liu, W.; Li, J.; Huang, Y.-Y.*; Li, B.*; Luo, H.-B.* Platycladus Orientalis (L.) Franco Demonstrates Effective Anti-Psoriasis Effects by Inhibiting PDE4 with Favorable Safety Profiles. Chin. Chem. Lett. 2025, 36, 110795.
11) Cai, J.#; Zhou, Q.#; Qi, X.; Zhang, F.; Yang, J.; Chen, C.; Zhang, K.; Chen, Z.; Luo, H.-B; Liu, Y.; Huang, Y.-Y.*; Zhou, X.* Discovery of Oxidized p-Terphenyls as Phosphodiesterase 4 Inhibitors from Marine-Derived Fungi. J. Nat. Prod. 2024, 87, 1808-1816.
12) Wu, D.#; Zheng, X.#; Liu, R.; Li, Z.; Jiang, Z.; Zhou, Q.; Huang, Y.; Wu, X.-N.; Zhang, C.; Huang, Y.-Y.*; Luo, H.-B.* Free Energy Perturbation (FEP)-Guided Scaffold Hopping. Acta Pharm. Sin. B. 2022, 12: 1351-1362.
13) Song, Z.#; Huang, Y.-Y.#; Hou, K.-Q.#; Liu, L.; Zhou, F.; Huang, Y.; Wan, G.; Luo, H.-B.*; Xiong, X.-F.* Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. J. Med. Chem. 2022, 65: 4238-4254.
14) Liu, H.#; Wang, Q.#; Huang, Y. #; Deng, J.; Xie, X.; Zhu, J.; Yuan, Y.; He, Y.-M.; Huang, Y.-Y.*; Luo, H.-B.*; He, X.* Discovery of Novel PDE4 Inhibitors Targeting the M-pocket from Natural Mangostanin with Improved Safety for the Treatment of Inflammatory Bowel Diseases. Eur. J. Med. Chem. 2022, 242: 114631.
15) Zhou, F.; Huang, Y.; Liu, L.; Song, Z.; Hou, K.-Q.; Yang, Y.; Luo, H.-B.; Huang, Y.-Y.*; Xiong, X.-F.* Structure-based Optimization of Toddacoumalone as Highly Potent and Selective PDE4 Inhibitors with Anti-inflammatory Effects. Biochem. Pharmacol. 2022, 202: 115123.
16) Huang, Y.-Y.#; Deng, J.#; Tian, Y.-J.#; Liang, J.; Xie, Xi.; Huang, Y.; Zhu, J.; Zhu, Z.; Zhou, Q.; He, X.*; Luo, H.-B.* Mangostanin Derivatives as Novel and Orally Active PDE4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J. Med. Chem. 2021, 64: 13736-13751.
17) Yang, Y.#; Zhang, S.#; Zhou, Q.#; Zhang, C.; Gao, Y.; Wang, Hao.; Li, Z.; Wu, D.; Wu, Y.; Huang, Y.-Y.*; Guo, L.*; Luo, H.-B.* Discovery of Highly Selective and Orally Available Benzimidazole-based Phosphodiesterase 10 Inhibitors with Improved Solubility and Pharmacokinetic Properties for Treatment of Pulmonary Arterial Hypertension. Acta Pharm. Sin. B. 2020, 10: 2339-2347.
18) Liang, J.#; Huang, Y.-Y.#; Zhou, Q.#; Gao, Y.; Li, Z.; Wu, D.; Yu, S.; Guo, L.; Chen, Z.; Huang, L.; Liang, S. H.; He, X.*; Wu, R.*; Luo, H.-B.* Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia. J. Med. Chem. 2020, 63: 3370-3380.
19) Li, Z.#; Li, X.#; Huang, Y.-Y.#; Wu, Y.; Liu, R.; Zhou, L.; Lin, Y.; Wu, D.; Zhang, L.; Liu, H.; Xu, X.; Yu, K.; Zhang, Y.; Cui, J.*; Zhan, C.-G.*; Wang, X.*; Luo, H.-B.* Identify Potent SARS-CoV-2 Main Protease Inhibitors via Accelerated Free Energy Perturbation-based Virtual Screening of Existing Drugs. Proc. Natl. Acad. Sci. USA. 2020, 117: 27381-27387.
20) Huang, Y.-Y.#; Yu, Y. -F.#; Zhang, C.#; Chen, Y.; Zhou, Q.; Li, Z.; Zhou, S.; Li, Z.; Guo, L.; Wu, D.*; Wu, Y.*; Luo, H.-B.* Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. J. Med. Chem. 2019, 62: 3707-3721.
21) Li, Z.#; Huang, Y.-Y.#; Wu, Y.; Chen, J.; Wu, D.; Zhan, C.-G.*; Luo, H.-B.* Absolute Binding Free Energy Calculation and Design of a Subnanomolar Inhibitor of Phosphodiesterase-10. J. Med. Chem. 2019, 62: 2099-2111.
22) Huang, Y.-Y.#; Liu, X.#; Wu, D.; Tang, G.; Lai, Z.; Zheng, X.*; Yin, S.*; Luo, H.-B.* The Discovery, Complex Crystal Structure, and Recognition Mechanism of a Novel Natural PDE4 Inhibitor from Selaginella Pulvinata. Biochem. Pharmacol. 2017, 130: 51-59.
23) Huang, Y.-Y.; Li, Z.; Cai, Y.; Feng, L.; Wu, Y.; Li, X.; Luo, H.-B.* The Molecular Basis for the Selectivity of Tadalafil Toward Phosphodiesterase 5 and 6: a Modeling Study. J. Chem. Inf. Model. 2013, 53: 3044-3053.
6. 荣誉奖励
1) 2025年全国大学生生命科学竞赛（科学探究类）海南赛区三等奖，指导老师；
2) 第十七届“全国大学生药苑论坛”创新成果三等奖，指导老师；
3) 海南省第三届“优秀研究生导师团队”荣誉称号，团队成员；
4) 海南省“四方之才”汇聚计划“优秀人才团队”荣誉称号，团队成员；
5) “海南省人才团队”荣誉称号，团队成员。
欢迎有药学、生物学、化学等相关学科背景的同学报考本课题组研究生。
联系地址：海南大学药学院
联系电话/传真：0898-66254967
E-mail：yxyyb@hainanu.edu.cn